Stalled Amyloid-β Production as a Contributing Cause of Alzheimer's Disease

It took twenty years of work and enormous expenditure, but the most recent immunotherapies targeting amyloid-β are capable of clearing most of this form of amyloid from the brain. Unfortunately, this class of therapy produces very little gain for patients in the later stages of Alzheimer's disease. ...